Reducing the impact of migraine on functioning: Results from the STRIVE trial, a phase 3, randomised, double-blind, placebo-controlled study of erenumab in patients with episodic migraine

被引：0
|
作者：
Buse, Dawn C. [1 ,2 ]
Lipton, Richard B. [1 ,2 ]
Mikol, Daniel D. [3 ]
Thach, Andrew V. [3 ]
Desai, Pooja [3 ]
Picard, Hernan [3 ]
Kubo, Yumi [3 ]
Hareendran, Asha [4 ]
Kawata, Ariane K. [5 ]
机构：
[1] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[2] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Evidera, London, England
[5] Evidera, Bethesda, MD USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P98
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy of Fremanezumab Treatment in Patients ≥60 Years of Age With Episodic or Chronic Migraine: Pooled Results of 3 Randomised, Double-blind, Placebo-controlled Phase 3 Studies
    Nahas, S. J.
    Ning, X.
    Cohen, J. M.
    Yang, R.
    Ramirez-Campos, V.
    Silberstein, S. D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 302 - 302
  • [32] Use of acute headache and migraine medications in patients with episodic migrainein the STRIVE Phase 3 trial of erenumab for migraine prevention
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Picard, Hernan
    Cheng, Sunfa
    Zhang, Feng
    Mikol, Dan
    Klatt, Jan
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [33] Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
    Reuter, Uwe
    Goadsby, Peter J.
    Lanteri-Minet, Michel
    Wen, Shihua
    Hours-Zesiger, Peggy
    Ferrari, Michel D.
    Klatt, Jan
    LANCET, 2018, 392 (10161): : 2280 - 2287
  • [34] Botulinum toxin A in the prophylactic treatment of migraine - a randomised, double-blind, placebo-controlled study
    Schwaag, S
    Vollmer-Haase, J
    Rahmann, A
    Frese, A
    Husstedt, IW
    Evers, S
    CEPHALALGIA, 2003, 23 (07) : 702 - 702
  • [35] Eletriptan for the acute treatment of migraine in adolescents: Results of a double-blind, placebo-controlled trial
    Winner, Paul
    Linder, Steven L.
    Lipton, Richard B.
    Almas, Mary
    Parsons, Bruce
    Pitman, Verne
    HEADACHE, 2007, 47 (04): : 511 - 518
  • [36] Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study
    Hauge, Anne W.
    Asghar, Mohammed S.
    Schytz, Henrik W.
    Christensen, Karl
    Olesen, Jes
    LANCET NEUROLOGY, 2009, 8 (08): : 718 - 723
  • [37] Impact of Galcanezumab on Total Pain Burden: Findings from Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies in Patients with Episodic or Chronic Migraine
    Ailani, Jessica
    Andrews, J. Scott
    Rettiganti, Mallikarjuna
    Nicholson, Robert
    NEUROLOGY, 2020, 94 (15)
  • [38] Magnesium in the prophylaxis of migraine - A double-blind, placebo-controlled study
    Pfaffenrath, V
    Wessely, P
    Meyer, C
    Isler, HR
    Evers, S
    Grotemeyer, KH
    Taneri, Z
    Soyka, D
    Gobel, H
    Fischer, M
    CEPHALALGIA, 1996, 16 (06) : 436 - 440
  • [39] A randomised, double-blind, placebo-controlled study of erenumab safety in patients with stable angina
    Depre, Christophe
    Antalik, Lubomir
    Starling, Amaal
    Koren, Michael
    Eisele, Osaro
    Mikol, Daniel D.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [40] Topiramate in migraine prevention: A double-blind, placebo-controlled study
    Storey, JR
    Calder, CS
    Hart, DE
    Potter, DL
    HEADACHE, 2001, 41 (10): : 968 - 975
12345